ELISA/assay

Canine Osteopontin, OPN ELISA Kit

MBS704021

48-Strip-Wells

605 USD

ELISA Kit

Canine Osteopontin, OPN ELISA Kit

Osteopontin, OPN

Canine Osteopontin; OPN ELISA Kit; Osteopontin; OPN

osteopontin; Osteopontin; osteopontin; uropontin; nephropontin; SPP1/CALPHA1 fusion; urinary stone protein; early T-lymphocyte activation 1; osteopontin/immunoglobulin alpha 1 heavy chain constant region fusion protein; secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1); secreted phosphoprotein 1; Bone sialoprotein 1; Nephropontin; Secreted phosphoprotein 1; SPP-1; Urinary stone protein; Uropontin

OPN

SPP1; SPP1; OPN; BNSP; BSPI; ETA-1; BNSP; OPN; PSEC0156; SPP-1

OSTP_HUMAN

Dog

300

This assay has high sensitivity and excellent specificity for detection of canine OPN. No significant cross-reactivity or interference between canine OPN and analogues was observed.

Unopened test kits should be stored at 2 to 8 degree C upon receipt. Please refer to pdf manual for further storage instructions.

Samples: Serum, plasma, tissue homogenates. Assay Type: Sandwich. Detection Range: 12.5 ng/ml -800ng/ml. Sensitivity: The minimum detectable dose of canine OPN is typically less than 3.12 ng/ml. The sensitivity of this assay, or Lower Limit of Detection (LLD) was defined as the lowest protein concentration that could be differentiated from zero. It was determined the mean O.D value of 20 replicates of the zero standard added by their three standard deviations.

Intra-assay Precision: Intra-assay Precision (Precision within an assay): CV%<8%. Three samples of known concentration were tested twenty times on one plate to assess. Inter-assay Precision: Inter-assay Precision (Precision between assays): CV%<10%. Three samples of known concentration were tested in twenty assays to assess.

Principle of the assay: This assay employs the quantitative sandwich enzyme immunoassay technique. Antibody specific for OPN has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any OPN present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for OPN is added to the wells. After washing, avidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of OPN bound in the initial step. The color development is stopped and the intensity of the color is measured.

189405

AAA59974.1

P10451

33,843 Da

BDNF Signaling Pathway (712093); Degradation Of The Extracellular Matrix Pathway (576263); Direct P53 Effectors Pathway (137939); ECM-receptor Interaction Pathway (83068); ECM-receptor Interaction Pathway (479); Endochondral Ossification Pathway (198812); Extracellular Matrix Organization Pathway (576262); FGF Signaling Pathway (137989); Focal Adhesion Pathway (198795); Focal Adhesion Pathway (83067)

The protein encoded by this gene is involved in the attachment of osteoclasts to the mineralized bone matrix. The encoded protein is secreted and binds hydroxyapatite with high affinity. The osteoclast vitronectin receptor is found in the cell membrane and may be involved in the binding to this protein. This protein is also a cytokine that upregulates expression of interferon-gamma and interleukin-12. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2011]

Function: Binds tightly to hydroxyapatite. Appears to form an integral part of the mineralized matrix. Probably important to cell-matrix interaction.

48-Strip-Wells

605 USD

96-Strip-Wells

870

5x96-Strip-Wells

2950

10x96-Strip-Wells

5535